RESUMEN
COVID-19 is a highly heterogeneous and complex medical disorder; indeed, severe COVID-19 is probably amongst the most complex of medical conditions known to medical science. While enormous strides have been made in understanding the molecular pathways involved in patients infected with coronaviruses an overarching and comprehensive understanding of the pathogenesis of COVID-19 is lacking. Such an understanding is essential in the formulation of effective prophylactic and treatment strategies. Based on clinical, proteomic, and genomic studies as well as autopsy data severe COVID-19 disease can be considered to be the connection of three basic pathologic processes, namely a pulmonary macrophage activation syndrome with uncontrolled inflammation, a complement-mediated endothelialitis together with a procoagulant state with a thrombotic microangiopathy. In addition, platelet activation with the release of serotonin and the activation and degranulation of mast cells contributes to the hyper-inflammatory state. Auto-antibodies have been demonstrated in a large number of hospitalized patients which adds to the end-organ damage and pro-thrombotic state. This paper provides a clinical overview of the major pathogenetic mechanism leading to severe COVID-19 disease.
Asunto(s)
COVID-19/virología , SARS-CoV-2/patogenicidad , COVID-19/sangre , COVID-19/inmunología , COVID-19/fisiopatología , Activación de Complemento , Proteínas del Sistema Complemento/metabolismo , Citocinas/sangre , Progresión de la Enfermedad , Interacciones Huésped-Patógeno , Humanos , Inflamación/sangre , Inflamación/inmunología , Inflamación/fisiopatología , Inflamación/virología , Mediadores de Inflamación/sangre , Síndrome de Activación Macrofágica/sangre , Síndrome de Activación Macrofágica/inmunología , Síndrome de Activación Macrofágica/fisiopatología , Síndrome de Activación Macrofágica/virología , Activación Plaquetaria , SARS-CoV-2/inmunología , Serotonina/sangre , Índice de Severidad de la Enfermedad , Microangiopatías Trombóticas/sangre , Microangiopatías Trombóticas/inmunología , Microangiopatías Trombóticas/fisiopatología , Microangiopatías Trombóticas/virologíaAsunto(s)
COVID-19/sangre , Megacariocitos/fisiología , Púrpura Trombocitopénica Idiopática/sangre , SARS-CoV-2 , Trombofilia/etiología , COVID-19/complicaciones , Citocinas/fisiología , Humanos , Pulmón/patología , Microcirculación , Modelos Biológicos , Púrpura Trombocitopénica Idiopática/complicaciones , Púrpura Trombocitopénica Idiopática/epidemiología , Receptores de Trombopoyetina/agonistas , Factores de Riesgo , Trombofilia/sangre , Trombofilia/epidemiología , Trombopoyesis , Trombopoyetina/metabolismo , Microangiopatías Trombóticas/sangre , Microangiopatías Trombóticas/etiología , Microangiopatías Trombóticas/fisiopatología , Factor de von Willebrand/metabolismoAsunto(s)
COVID-19/sangre , Inhibidor 1 de Activador Plasminogénico/sangre , SARS-CoV-2 , Activador de Tejido Plasminógeno/sangre , Anciano , Biomarcadores , Proteínas Sanguíneas/análisis , COVID-19/complicaciones , COVID-19/mortalidad , Comorbilidad , Progresión de la Enfermedad , Femenino , Fibrinólisis , Humanos , Inflamación , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Pronóstico , Estudios Prospectivos , Alveolos Pulmonares/fisiopatología , Índice de Severidad de la Enfermedad , Microangiopatías Trombóticas/sangre , Microangiopatías Trombóticas/etiologíaRESUMEN
Influenza virus can trigger atypical hemolytic uremic syndrome and present with complement-driven thrombotic microangiopathy (TMA). When administered promptly, complement-blocking therapies can spare organ injury and be lifesaving. However, diagnosing TMA in the setting of a severe viral infection can be challenging, as a significant overlap of symptoms and disease complications exists. This is particularly true in influenza virus infections and more recently, Coronavirus disease 2019 (COVID-19) infections. We present a 16-year-old male with H1N1 influenza-induced atypical hemolytic uremic syndrome who quickly improved with complement-blocking therapy, highlighting an urgent need to include TMA in the differential diagnosis of severe viral infections.
Asunto(s)
Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/complicaciones , Microangiopatías Trombóticas/diagnóstico , Microangiopatías Trombóticas/virología , Adolescente , Anticuerpos Monoclonales Humanizados/uso terapéutico , Inactivadores del Complemento/uso terapéutico , Humanos , Gripe Humana/sangre , Gripe Humana/diagnóstico , Masculino , Microangiopatías Trombóticas/sangre , Microangiopatías Trombóticas/tratamiento farmacológicoRESUMEN
The core pathology of coronavirus disease 2019 (COVID-19) is infection of airway cells by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive inflammation and respiratory disease, with cytokine storm and acute respiratory distress syndrome implicated in the most severe cases. Thrombotic complications are a major cause of morbidity and mortality in patients with COVID-19. Patients with pre-existing cardiovascular disease and/or traditional cardiovascular risk factors, including obesity, diabetes mellitus, hypertension and advanced age, are at the highest risk of death from COVID-19. In this Review, we summarize new lines of evidence that point to both platelet and endothelial dysfunction as essential components of COVID-19 pathology and describe the mechanisms that might account for the contribution of cardiovascular risk factors to the most severe outcomes in COVID-19. We highlight the distinct contributions of coagulopathy, thrombocytopathy and endotheliopathy to the pathogenesis of COVID-19 and discuss potential therapeutic strategies in the management of patients with COVD-19. Harnessing the expertise of the biomedical and clinical communities is imperative to expand the available therapeutics beyond anticoagulants and to target both thrombocytopathy and endotheliopathy. Only with such collaborative efforts can we better prepare for further waves and for future coronavirus-related pandemics.